Group 1 - On October 15, Samsung Medical's stock rose by 2.07%, with a trading volume of 555 million yuan [1] - The financing data shows that on the same day, Samsung Medical had a financing purchase amount of 54.05 million yuan and a net financing purchase of 9.43 million yuan [1] - As of October 15, the total balance of margin trading for Samsung Medical was 375 million yuan, with a financing balance of 372 million yuan, accounting for 1.01% of the circulating market value [1] Group 2 - As of June 30, the number of shareholders of Samsung Medical increased to 29,000, a rise of 76.91%, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2] - For the first half of 2025, Samsung Medical achieved an operating income of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit attributable to the parent company of 1.230 billion yuan, up 6.93% year-on-year [2] Group 3 - Samsung Medical has distributed a total of 6.407 billion yuan in dividends since its A-share listing, with 3.329 billion yuan distributed in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 47.9803 million shares, an increase of 3.9134 million shares compared to the previous period [3]

分红方面，三星医疗A股上市后累计派现57.28亿元。近三年，累计派现26.50亿元。 机构持仓方面，截止2025年6月30日，三星医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股4798.03万股，相比上期增加391.34万股。 责任编辑：小浪快报 资料显示，宁波三星医疗电气股份有限公司位于浙江省宁波市鄞州工业园区(宁波市鄞州区姜山镇)，成 立日期2007年2月1日，上市日期2011年6月15日，公司主营业务涉及电能计量及信息采集产品、配电设 备的研发、生产和销售。医疗服务业务。主营业务收入构成为：电力板块收入79.70%，医疗服务收入 19.15%，其他业务收入1.15%，融资租赁及咨询服务收入0.00%。 截至6月30日，三星医疗股东户数2.90万，较上期增加76.91%；人均流通股48732股，较上期减少 43.15%。2025年1月-6月，三星医疗实现营业收入79.72亿元，同比增长13.93%；归母净利润12.30亿元， 同比增长6.93%。 9月29日，三星医疗跌0.37%，成交额5.76亿元。两融数据显示，当日三星医疗获融资买入额5617.64万 元，融资偿还4524.94万元 ...

Company Overview - SamSung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, SamSung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 5.728 billion yuan in dividends, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 22, SamSung Medical's stock price was 22.49 yuan per share, with a market capitalization of 31.603 billion yuan. The stock has declined by 24.72% year-to-date and has seen a slight decrease of 0.79% over the past five trading days [1]. - The company has a total of 29,000 shareholders as of June 30, with an average of 48,732 circulating shares per shareholder, a decrease of 43.15% from the previous period [2]. Shareholder Composition - As of June 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The main business revenue composition of SamSung Medical includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses. The company is categorized under the electric equipment industry, specifically in power grid equipment and distribution equipment [1].

Company Overview - Samsung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 5.728 billion yuan, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 18, Samsung Medical's stock price decreased by 2.02%, trading at 22.75 yuan per share, with a total market capitalization of 31.969 billion yuan. The stock has declined by 23.85% year-to-date [1]. - The stock's trading volume showed a net inflow of 4.8744 million yuan from main funds, with significant buying and selling activities recorded [1]. Shareholder Information - As of June 30, the number of shareholders increased to 29,000, up by 76.91%, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The company's main business revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1]. - Samsung Medical is categorized under the electric equipment industry, specifically in the distribution equipment sector, and is associated with concepts such as private hospitals, mid-cap stocks, electric IoT, industrial internet, and energy storage [1].

Company Overview - Samsung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 5.728 billion yuan, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 17, Samsung Medical's stock price was 22.98 yuan per share, with a market capitalization of 32.292 billion yuan. The stock has decreased by 23.08% year-to-date but has seen a slight increase of 1.01% over the last five trading days [1]. - The company experienced a net inflow of main funds amounting to 5.7457 million yuan, with significant buying and selling activity from large orders [1]. Shareholder Information - As of June 30, the number of shareholders for Samsung Medical reached 29,000, an increase of 76.91% from the previous period. The average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The company's main business revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1]. - Samsung Medical operates within the electric equipment industry, specifically in the distribution equipment sector, and is associated with concepts such as private hospitals, mid-cap companies, industrial internet, electric power IoT, and charging piles [1].

Core Insights - Samsung Medical experienced a stock decline of 0.34% on August 25, with a trading volume of 991 million yuan [1] - The company reported a financing buy-in of 139 million yuan and a repayment of 110 million yuan on the same day, resulting in a net financing buy of 29.26 million yuan [1] - As of August 25, the total financing and securities lending balance for Samsung Medical was 492 million yuan, with a financing balance of 489 million yuan, accounting for 1.49% of the circulating market value, indicating a high level compared to the past year [1] Financing and Securities Lending - On August 25, Samsung Medical had a securities lending repayment of 300 shares and sold 19,100 shares, amounting to 445,600 yuan based on the closing price [1] - The remaining securities lending volume was 127,500 shares, with a balance of 2.97 million yuan, which is below the 30th percentile of the past year, indicating a low level [1] Company Overview - Samsung Medical Electric Co., Ltd. is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011 [1] - The company's main business includes the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1] - The revenue composition of Samsung Medical is as follows: smart distribution and utilization of electricity 76.16%, medical services 22.31%, other (supplementary) 1.48%, and financing leasing and consulting services 0.04% [1] Financial Performance - As of June 30, the number of shareholders for Samsung Medical reached 29,000, an increase of 76.91% compared to the previous period [2] - The average circulating shares per person decreased by 43.15% to 48,732 shares [2] - For the first half of 2025, Samsung Medical achieved an operating income of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit attributable to shareholders of 1.230 billion yuan, up 6.93% year-on-year [2] Dividend Distribution - Since its A-share listing, Samsung Medical has distributed a total of 5.728 billion yuan in dividends, with 2.650 billion yuan distributed over the past three years [2] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 47.9803 million shares, an increase of 3.9134 million shares compared to the previous period [2]

Group 1 - The core viewpoint of the news is that Samsung Medical has shown revenue growth in the first half of 2025, but its profitability is under pressure, with a reported revenue of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit of 1.230 billion yuan, up 6.93% [1][3] - The company's profitability indicators have declined significantly, with net profit margin dropping from 16.49% to 15.24%, and gross profit margin decreasing from 34.61% to 28.97%, a decline of 5.64 percentage points [3] - The company is facing challenges in cash flow, with a negative net cash flow from operating activities of -0.059 billion yuan, compared to a positive 0.26 billion yuan in the same period last year, indicating difficulties in cash recovery [5] Group 2 - The number of institutional investors holding Samsung Medical shares has decreased dramatically from 666 to 39, reflecting a significant decline in investor confidence [7] - The company's asset-liability ratio has increased to 46.62%, up 2.92 percentage points year-on-year, indicating a heavier debt burden [5] - To reach its historical peak market value of 54.129 billion yuan, the current market value of 34.653 billion yuan would need to increase by 56.20%, highlighting the need for the company to improve operational efficiency and rebuild market confidence [7]